Immunolabelling for C3aR was observed in 90% of MS sections and 40% of non-neurological controls (p = 0.004, s0al Figure 4) whereas C5aR was observed in the majority of MS and control sections, although the number of immunolabelled cells in MS cases and neurological controls was almost 3-fold higher compared to non-neurological controls (p < 0.001 for both C3aR and C5aR; Figure 2). The gene discussed is C5AR1; the disease is myeloid sarcoma.